In this sense, the fact that MjTX-I activated caspase 3 through the intrinsic and extrinsic apoptosis pathways, downregulated BCL-2 expression, and upregulated BAD expression indicate that this toxin is a promising molecule for the adjuvant treatment of CML. This evidence concerns the gene CASP3 and chronic myelogenous leukemia, BCR-ABL1 positive.